Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors

被引：72
作者：
Guan, Ronggui [1 ]
Xu, Xiaoyu [1 ]
Chen, Meihui [1 ]
Hu, Haiyan [1 ]
Ge, Hu [1 ]
Wen, Shijun [2 ]
Zhou, Shiyou [3 ]
Pi, Rongbiao [1 ]
机构：
[1] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2013年 / 70卷
基金：
中国国家自然科学基金;
关键词：
RhoA; Rho kinase; Inhibitors; Central nervous system; Fasudil; CENTRAL-NERVOUS-SYSTEM; RHO-ASSOCIATED KINASE; ROCK INHIBITORS; THERAPEUTIC TARGET; FASUDIL; DISCOVERY; POTENT; OPTIMIZATION; DERIVATIVES; 7-AZAINDOLES;
D O I：
10.1016/j.ejmech.2013.10.048
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
RhoA/Rho-kinase pathway plays a pivotal role in numerous fundamental cellular functions including contraction, motility, proliferation, differentiation and apoptosis. The pathway is also involved in the development of many diseases such as vasospasm, pulmonary hypertension, cancer and central nervous systems (CNS) disorders. The inhibitors of Rho kinase have been extensively studied since the Rho/Rho-kinase pathway was verified as a target for a number of diseases. Herein, we reviewed the advances in the studies of the roles of Rho/Rho-kinase in diseases and the development of Rho-kinase inhibitors in recent five years. (C) 2013 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：613 / 622
页数：10
相关论文
共 71 条
[1]   Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: Part 3, aryl substituted pyrrolidines [J].
Bosanac, Todd ;
Hickey, Eugene R. ;
Ginn, John ;
Kashem, Mohammed ;
Kerr, Steven ;
Kugler, Stanley ;
Li, Xiang ;
Olague, Alan ;
Schlyer, Sabine ;
Young, Erick R. R. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (12) :3746-3749
[2]   Fasudil and its analogs: a new powerful weapon in the long war against central nervous system disorders? [J].
Chen, Meihui ;
Liu, Anmin ;
Ouyang, Ying ;
Huang, Yingjuan ;
Chao, Xiaojuan ;
Pi, Rongbiao .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (04) :537-550
[3]   Chroman-3-amides as potent Rho kinase inhibitors [J].
Chen, Yen Ting ;
Bannister, Thomas D. ;
Weiser, Amiee ;
Griffin, Evelyn ;
Lin, Li ;
Ruiz, Claudia ;
Cameron, Michael D. ;
Schurer, Stephan ;
Duckett, Derek ;
Schroter, Thomas ;
LoGrasso, Philip ;
Feng, Yangbo .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (24) :6406-6409
[4]  
Chowdhury S, 2011, BIOORG MED CHEM LETT, V21, P7107, DOI 10.1016/j.bmcl.2011.09.083
[5]   The hydrophobic motif of ROCK2 requires association with the N-terminal extension for kinase activity [J].
Couzens, Amber L. ;
Saridakis, Vivian ;
Scheid, Michael P. .
BIOCHEMICAL JOURNAL, 2009, 419 :141-148
[6]   A combination of increased Rho kinase activity and N-terminal pro-B-type natriuretic peptide predicts worse cardiovascular outcome in patients with acute coronary syndrome [J].
Dong, Ming ;
Liao, James K. ;
Yan, Bryan ;
Li, Ruijie ;
Zhang, Mang ;
Yu, Cheuk-Man .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 167 (06) :2813-2819
[7]   Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases [J].
Dong, Ming ;
Yan, Bryan P. ;
Liao, James K. ;
Lam, Yat-Yin ;
Yip, Gabriel W. K. ;
Yu, Cheuk-Man .
DRUG DISCOVERY TODAY, 2010, 15 (15-16) :622-629
[8]   New insights into the structure-function relationships of Rho-associated kinase: a thermodynamic and hydrodynamic study of the dimer-to-monomer transition and its kinetic implications [J].
Doran, JD ;
Liu, X ;
Taslimi, P ;
Saadat, A ;
Fox, T .
BIOCHEMICAL JOURNAL, 2004, 384 :255-262
[9]  
Duan Wei-gang, 2007, Yaoxue Xuebao, V42, P1013
[10]   Structural insights into the interaction of ROCKI with the switch regions of RhoA [J].
Dvorsky, R ;
Blumenstein, L ;
Vetter, IR ;
Ahmadian, MR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (08) :7098-7104
12345678